STOCK TITAN

Avidity Biosciences, Inc. - RNA STOCK NEWS

Welcome to our dedicated page for Avidity Biosciences news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences stock.

Avidity Biosciences, Inc. (Nasdaq: RNA) is a pioneering biopharmaceutical company dedicated to revolutionizing RNA therapeutics with its proprietary Antibody Oligonucleotide Conjugates (AOCs™). Their innovative approach merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted treatment of diseases that were previously unreachable with existing RNA therapies. They are at the forefront of developing therapies for serious genetic conditions, predominantly focusing on rare muscle diseases.

Avidity's leading clinical programs include:

  • AOC 1001 (Del-desiran): Targeting Myotonic Dystrophy Type 1 (DM1), a disease with no approved therapies. Del-desiran has shown promising long-term data from the MARINA-OLE™ trial, demonstrating reversal of disease progression in patients. The global Phase 3 HARBOR™ trial is set to begin, with video hand opening time (vHOT) as the primary endpoint.
  • AOC 1044: Aimed at Duchenne Muscular Dystrophy (DMD) with mutations amenable to exon 44 skipping. Recently, it achieved Rare Pediatric Disease and Orphan Drug designations from the FDA and EMA. Positive preliminary data has been reported from the Phase 1/2 EXPLORE44™ clinical trial.
  • AOC 1020: Focused on Facioscapulohumeral Muscular Dystrophy (FSHD). Clinical data from the Phase 1/2 FORTITUDE™ trial is expected soon.

Avidity is also advancing its pipeline to include cardiology and immunology programs, aiming to target a broader range of diseases. The company has garnered support and collaborations with top-tier investors and strategic partners, enhancing its capability to deliver groundbreaking treatments.

With headquarters in San Diego, CA, Avidity Biosciences is committed to transforming lives through innovative RNA therapeutics. For more information, visit www.aviditybiosciences.com.

Rhea-AI Summary
Avidity Biosciences to present two poster presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
conferences
-
Rhea-AI Summary
Avidity Biosciences announces participation in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences
-
Rhea-AI Summary
Avidity Biosciences grants stock options and restricted stock units to new non-executive employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
Rhea-AI Summary
Avidity Biosciences has received Orphan Drug designation from the FDA for its investigational therapy, AOC 1044, for the treatment of Duchenne muscular dystrophy (DMD) in patients with exon 44 skipping mutations. AOC 1044 is being assessed in the EXPLORE44 clinical trial and is the first of multiple AOCs in development for DMD. Avidity plans to share results from the trial in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
-
Rhea-AI Summary
Avidity Biosciences grants stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
none
Rhea-AI Summary
Avidity Biosciences, Inc. will be participating in the TD Cowen 2nd Annual RNA Therapeutics Summit on July 10. The event will be live webcasted and available for replay on Avidity's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
conferences

FAQ

What is the current stock price of Avidity Biosciences (RNA)?

The current stock price of Avidity Biosciences (RNA) is $43.25 as of November 22, 2024.

What is the market cap of Avidity Biosciences (RNA)?

The market cap of Avidity Biosciences (RNA) is approximately 5.2B.

What is Avidity Biosciences, Inc.?

Avidity Biosciences, Inc. is a biopharmaceutical company pioneering RNA therapeutics with its proprietary Antibody Oligonucleotide Conjugates (AOCs™) to treat serious genetic diseases.

What are Antibody Oligonucleotide Conjugates (AOCs™)?

AOCs™ combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted treatment of diseases previously unreachable with existing RNA therapies.

What is AOC 1001 (Del-desiran)?

AOC 1001 (Del-desiran) is Avidity's lead product candidate for treating Myotonic Dystrophy Type 1 (DM1). It has shown promising results in clinical trials and is entering global Phase 3 HARBOR™ trial.

What are the key clinical programs of Avidity Biosciences?

The key clinical programs include AOC 1001 for DM1, AOC 1044 for Duchenne Muscular Dystrophy (DMD) with exon 44 skipping, and AOC 1020 for Facioscapulohumeral Muscular Dystrophy (FSHD).

What designations has AOC 1044 received?

AOC 1044 has received Rare Pediatric Disease, Orphan Drug, and Fast Track designations from the FDA and EMA for its potential to treat Duchenne Muscular Dystrophy (DMD) with exon 44 skipping.

What is the significance of the MARINA-OLE™ trial?

The MARINA-OLE™ trial demonstrated that AOC 1001 (Del-desiran) can reverse disease progression in Myotonic Dystrophy Type 1 (DM1) patients, showing improvements in key metrics such as video hand opening time (vHOT) and muscle strength.

What other areas is Avidity Biosciences expanding into?

In addition to rare muscle diseases, Avidity Biosciences is expanding its pipeline to include cardiology and immunology programs through internal discovery efforts and key partnerships.

Where is Avidity Biosciences headquartered?

Avidity Biosciences is headquartered in San Diego, CA.

How is Avidity Biosciences funded?

Avidity Biosciences is supported by top-tier investors and partnerships, recently completing an oversubscribed equity raise of $400 million, securing its financial position to fund operations into late 2026.

How can I learn more about Avidity Biosciences?

For more information, visit their official website at www.aviditybiosciences.com.

Avidity Biosciences, Inc.

Nasdaq:RNA

RNA Rankings

RNA Stock Data

5.18B
112.41M
4.83%
106.29%
12.29%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO